Low dose nivolumab in metastatic mucosal melanoma: a case report
Abstract We present the case of a 77-year-old man with metastatic mucosal melanoma, unable to afford standard doses of immunotherapy, who was treated with nivolumab at a lower dose of 0.5 mg/kg every 2 weeks. Drug activity was demonstrated through both objective tumor response and an immune-related adverse event. This suggests that a lower dose of nivolumab could be a viable alternative for patients with advanced mucosal melanoma at a high risk of treatment-related financial toxicity. Further research is needed to evaluate the efficacy of lower doses of immunotherapy, including its impact on long term outcomes.
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Sociedad Mexicana de Oncología A.C.
2023
|
| Online Access: | http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2565-005X2023000300140 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|